Weight-Loss Agents
Novo Nordisk Seeks FDA Ban on Compounded Semaglutide Formulations Amid Safety Concerns
Novo Nordisk, FDA, semaglutide, compounding pharmacies, safety concerns, GLP-1 medications, weight loss drugs, diabetes treatments
Lilly’s Obesity Drug Shortage Resolved, Novo’s Continues Amid Industry Efforts to Boost Manufacturing
Eli Lilly, obesity drug shortage, Mounjaro, Zepbound, Novo Nordisk, Wegovy, GLP-1 drugs, pharmaceutical manufacturing, weight loss drugs.
Eli Lilly and Novo Nordisk Support OAC’s Your Weight Matters Campaign Amidst Competitive Weight Loss Drug Market
Eli Lilly, Novo Nordisk, OAC, Your Weight Matters, weight loss drugs, GLP-1, obesity care, pharmaceutical industry
Eli Lilly Appoints Insider Lucas Montarce as Chief Financial Officer Amid Rising Demand for Weight Loss Drugs
Eli Lilly, Lucas Montarce, CFO, weight loss drugs, Mounjaro, Zepbound, pharmaceutical industry, leadership transition
BioAge Labs Files for IPO to Advance Obesity Treatment Candidate
BioAge Labs, IPO, obesity treatment, weight loss drugs, azelaprag, Eli Lilly, cardiometabolic biotech
Hims Secures Drug Supply for Thriving Weight Loss Business
Hims, weight loss drugs, compounded GLP-1, drug supply, booming business, revenue growth, subscriber base
Novo Nordisk’s Wegovy Sales Shortfall: A Rare Setback for the Danish Drugmaker
Novo Nordisk, Wegovy, weight-loss drug, sales shortfall, stock performance, pharmaceutical industry
EMA Dispels Link Between GLP-1 Receptor Agonists and Suicidal Ideation Risk New
EMA, GLP-1 receptor agonists, Diabetes and weight-loss drugs, Suicidal ideation risk, No causal association, Pharmacovigilance activities, Continued monitoring